Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • posting_clown posting_clown Nov 28, 2012 5:00 PM Flag

    ACTC Progress

     

    Black, seems like you've missed some of the press. From a NY Times article:

    "Both patients, who were legally blind, said in interviews that they had gains in eyesight that were meaningful for them. One said she could see colors better and was able to thread a needle and sew on a button for the first time in years. The other said she was able to navigate a shopping mall by herself. "

    "One woman, Sue Freeman, who is in her 70s, suffered from the dry form of age-related macular degeneration, a leading cause of severe vision loss in the elderly.

    The other, who asked that her name not be used to protect her privacy, was a 51-year-old graphic designer in Los Angeles with Stargardt’s macular dystrophy, which tends to occur in younger people."

    They weren't "cured" but the disease appears to have been halted and the experienced some improvement. Even these apparently lack luster results would make this a blockbuster treatment and well beyond anything out there.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • posting: yep, sure looks like I missed those reports. First time that I have heard of that!!!

      But, those reports raise a rather profound question in my mind.

      If ACTC is already seeing those sorts of significant human results, THEN, WHY IS THE STOCK PPS TRADING FOR UNDER A DIME? Doesn't make sense!

      I'm a little puzzled.

    • There's only one problem with your "blockbuster treatment" scenario, posting-clown......no one but you seems to believe it. The stock price reflects that.

    • The 50,000 and also the 100,000 cell dosages are meant for the safety evaluation and not so much for the efficacy. I understand, even 50,000 cell dosage must show some effect; but, keeping in view nearly blind patients, perhaps it needs a longer period and additional such injections to show significant improvement. The six-month period for the trial for each thus may not be enough to judge efficacy for 50,000 or even 100,000 cell dosages. The fact remains that after the two stages, there is absolutely no side effect (unlike OPC1!) and had an indication that there is some positive effect on the patients' vision. Of course more will be known soon since the second cohorts for both SMD and AMD are now done and they are moving to the third stage. However, we must be mindful that where the injected cells in the ACTC's trials affect only the retinal portion of the eye, injected cells in Geron's OPC1 trials affected almost the entire blood stream in the body. Thus, to answer Black's original post's comment regarding comparision of the cell quantities for the two, it is improper.

 
GERN
4.15-0.25(-5.68%)Jul 2 4:00 PMEDT